Table 3—

Distribution of adverse outcomes after 3 years among the four groups of the consensus classification

Group 0 (no neuropathy)OR (groups 1–3)Group 1 (neuropathy)OR (groups 1–3)Group 2 (neuropathy, vascular disease and/or deformityOR (groups 2–3)Group 3 (previous ulcer)TotalP
Follow-up ulcer4 (5.1)34.1 (11.0–105.8)3 (14.3)10.9 (2.9–41.2)7 (13.3)11.4 (4.4–29.6)40 (64.5)54 (25.4)<0.001
Follow-up amputation02.7 (2.2–3.4)01.4 (1.2–1.6)1 (2.0)17.4 (2.2–136.4)16 (25.8)17 (8.0)<0.001
Toe/ray001 (2.0)7 (11.3)8 (3.8)<0.001
Transmetatarsal0005 (8.1)5 (2.3)
Transtibial or higher0004 (6.5)4 (1.9)
Reamputations02.4 (2.0–3.0)01.4 (1.2–1.6)01.9 (1.6–2.3)7 (43.8)7 (41.1)0.001
Follow-up bypass02.4 (2.0–2.9)01.4 (1.2–1.6)1 (2.0)NS5 (8.1)6 (2.8)0.006
  • Data are n (%) and OR (95% CI) unless otherwise indicated. For follow-up ulcer, follow-up amputation, and for all amputations, P < 0.001; for reamputations, P = 0.001; and for follow-up bypass, P = 0.006.